BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
- Symbol
- BBIO
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $12.83B
- 52 week range
- 48.78 - 93.42
Valuation
- Share price
- $65.71 (close of 2026-09-23)
- P/E (TTM)
- -18.41x
- Price to book
- -5.12x
- Price to free cash flow
- -29.47x
- Enterprise value
- $14.65B
- Book value per share
- $-12.83
Price performance
| Period | Change |
|---|
| 1 day | -1.31% |
| 5 days | -3.92% |
| 1 month | -19.37% |
| 3 months | -4.25% |
| 6 months | -5.59% |
| Year to date | -14.09% |
| 1 year | +27.59% |
| 3 years | +140.96% |
| 5 years | +31.68% |
| All time | +138.52% |
Profitability and growth
- Return on equity
- 35.31%
- Return on assets
- -78.30%
- Return on capital employed
- -80.77%
- Gross margin
- 95.82%
- Net margin
- -145.98%
- EBITDA margin
- -103.17%
- Revenue growth
- 126.26%
- Net income growth
- -34.89%
- Free cash flow growth
- 14.31%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -3.39%
- Current ratio
- 1.23x
- Net debt to EBITDA
- -3.69x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $502.08M
- Cost of revenue
- $20.96M
- Gross profit
- $481.11M
- EBITDA
- $-517.98M
- Net income
- $-732.94M
- Earnings per share
- $-3.78
- Research and development
- $451.95M
- Shares outstanding
- 191.53M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $502.08M | $481.11M | $-732.94M | $-3.78 |
| 2024-12-31 | $221.90M | $218.02M | $-543.35M | $-2.88 |
| 2023-12-31 | $9.30M | $6.86M | $-653.25M | $-3.95 |
| 2022-12-31 | $77.65M | $74.21M | $-484.65M | $-3.26 |
| 2021-12-31 | $69.72M | $66.60M | $-586.45M | $-3.90 |
| 2020-12-31 | $8.25M | - | $-505.49M | $-3.80 |
| 2019-12-31 | $40.56M | $38.06M | $-288.58M | $-2.48 |
| 2018-12-31 | - | - | $-169.45M | $-2.12 |
| 2017-12-31 | - | - | $-43.83M | $-1.00 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 95.82% | -145.98% | 35.31% | - |
| 2024-12-31 | 98.25% | -244.86% | 37.27% | - |
| 2023-12-31 | 73.71% | -7021.94% | 48.64% | -2907.47% |
| 2022-12-31 | 95.58% | -624.17% | 38.98% | -494.69% |
| 2021-12-31 | 95.53% | -841.20% | 67.64% | - |
| 2020-12-31 | - | -6127.87% | -475.73% | - |
| 2019-12-31 | 93.84% | -711.50% | -60.92% | -126.93% |
| 2018-12-31 | - | - | -44.92% | - |
| 2017-12-31 | - | - | -49.61% | - |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $570.12M | $2.01B |
| 2024-12-31 | $681.10M | $437.34M |
| 2023-12-31 | $375.94M | $446.44M |
| 2022-12-31 | $376.69M | $430.99M |
| 2021-12-31 | $393.77M | $430.75M |
| 2020-12-31 | $356.08M | $92.42M |
| 2019-12-31 | $363.77M | $91.79M |
| 2018-12-31 | $436.09M | $54.51M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-447.01M | $133.02M |
| 2024-12-31 | $-521.66M | $95.80M |
| 2023-12-31 | $-529.03M | $108.71M |
| 2022-12-31 | $-424.31M | $91.56M |
| 2021-12-31 | $-511.18M | $99.50M |
| 2020-12-31 | $-407.23M | $58.46M |
| 2019-12-31 | $-256.23M | $21.37M |
| 2018-12-31 | $-138.82M | $6.07M |
| 2017-12-31 | $-40.95M | $1.84M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-10 | Jun/2026 | - |
| 2026-08-04 | - | - |
| 2026-05-07 | - | - |
| 2026-02-24 | - | - |
| 2025-10-29 | - | - |
| 2025-08-05 | - | - |
| 2025-04-29 | - | - |
| 2025-02-20 | - | - |
Filings and sources
- Company website
- bridgebio.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades